GRAVES DISEASE OVERACTIVE THYROID MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Regional Analysis

To learn more about this report, request sample copy

North America dominates the global graves' disease (overactive thyroid) market with estimated market share of 41.2% in 2024 The region has a strong presence of leading pharmaceutical companies focusing on research and development for novel graves’ disease treatment options. With growing prevalence of thyroid disorders and increasing healthcare expenditure in the U.S. and Canada, there has been huge demand for Graves’ disease medications. The region also has an well-developed regulatory framework and favorable reimbursement scenario supporting new product approvals. Thus, North American countries are quick to adopt novel therapeutic approaches and recently FDA-approved drugs compared to other regions.

Asia Pacific market is poised to emerge as the fastest growing regional market in the near future. Rising healthcare awareness coupled with improving access to healthcare facilities especially in developing countries like India and China can offer opportunities for market players. These nations have a large patient pool suffering from thyroid disorders owing to genetic risks and evolving lifestyle changes. Increasing local manufacturing of generic drugs has made Graves’ disease medications more affordable for patients in Asia Pacific. International players are also expanding their local production plants to cater to demand and leverage low-cost manufacturing advantages.